Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

triamcinolone acetonide extended-release injectable suspension

×

Overview

What is Zilretta?

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is a microsphere formulation of triamcinolone acetonide, a corticosteroid, to be administered by intra-articular injection.

ZILRETTA is formulated in 75:25 poly(lactic-co-glycolic acid) (PLGA) microspheres with a nominal drug load of 25% (w/w) and is provided as a sterile white to off-white powder. ZILRETTA is prepared with a supplied diluent containing an isotonic, sterile, aqueous solution of sodium chloride (NaCl; 0.9% w/w), sodium carboxymethylcellulose (CMC; 0.5% w/w) and polysorbate-80 (0.1% w/w) to form a 5 mL sterile suspension intended for intra-articular injection.



What does Zilretta look like?



What are the available doses of Zilretta?

ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter. ( )

What should I talk to my health care provider before I take Zilretta?

How should I use Zilretta?

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

32 mg administered as a single intra-articular injection in the knee. ( )

See (IFU) for instructions on reconstitution of ZILRETTA with the supplied diluent. ( )

It is normal for some residue to be left behind on the vial walls after withdrawing the suspension. ( )

Not interchangeable with other formulations of injectable triamcinolone acetonide. ( )


What interacts with Zilretta?

Sorry No Records found


What are the warnings of Zilretta?

Sorry No Records found


What are the precautions of Zilretta?

Sorry No Records found


What are the side effects of Zilretta?

Sorry No records found


What should I look out for while using Zilretta?

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product .


What might happen if I take too much Zilretta?

Sorry No Records found


How should I store and handle Zilretta?

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).NORVIR Tablets, 100 mg RitonavirNORVIR (ritonavir) tablets are white film-coated ovaloid tablets debossed with the "a" logo and the code NK.Bottles of 30 tablets each ( 0074-3333-30).Recommended StorageStore at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Dispense in original container or USP equivalent tight container (60 mL or less). For patient use: exposure of this product to high humidity outside the original or USP equivalent tight container (60 mL or less) for longer than 2 weeks is not recommended.NORVIR Oral Solution, 80 mg per mL RitonavirNORVIR (ritonavir) oral solution is an orange-colored liquid, supplied in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg per mL).240 mL bottles ( 0074-1940-63).Recommended StorageStore at room temperature 20°-25°C (68°-77°F). Do not refrigerate. Shake well before each use. Use by product expiration date.Product should be stored and dispensed in the original container.Avoid exposure to excessive heat. Keep cap tightly closed.NORVIR Oral Powder, 100 mg PacketNORVIR (ritonavir) oral powder is beige/pale yellow to yellow, supplied in packets containing 100 mg of ritonavir. 30 foil/laminate, child-resistant packets per carton ( 0074-3399-30).Recommended StorageStore at or below 30°C (86°F).


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.

Non-Clinical Toxicology
ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product .

Drug Interactions:

Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.

Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic diseases, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.

There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.

Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.

Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure. An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary.

Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.

In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Use of furosemide concomitantly with chloral hydrate is therefore not recommended.

Phenytoin interferes directly with renal action of furosemide.

Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide. Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide.

Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment.

Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion.

One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.

Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.

ZILRETTA has not been evaluated and should not be administered by the following routes:

[see Warnings and Precautions ( )].

The following serious adverse reactions are described elsewhere in the labeling.

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data below reflect exposure to a single 32 mg intra-articular injection of ZILRETTA in clinical studies in patients with moderate to severe pain due to osteoarthritis of the knee. Clinical studies included randomized, double-blind, parallel-group, placebo and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6-24 weeks. A total of 424 patients received ZILRETTA and 262 received placebo. Treatment emergent adverse reactions reported by greater than or equal to 1% of patients in the ZILRETTA arms are summarized below ( ).

Overall, the incidence and nature of adverse reactions was similar to that observed with placebo.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).